BCX4161, An Oral Kallikrein Inhibitor: Safety and Pharmacokinetic Results Of a Phase 1 Study In Healthy Volunteers

被引：1
|
作者：
Collis, Phil [1 ]
Cornpropst, Melanie [1 ]
Collier, Jo [2 ]
Sheridan, William [1 ]
机构：
[1] BioCryst Pharmaceut, Durham, NC USA
[2] Quotient Clin, Nottingham, England
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2014年 / 133卷 / 02期
关键词：
D O I：
10.1016/j.jaci.2013.12.162
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
138
引用
收藏
页码：AB39 / AB39
页数：1
相关论文
共 50 条
  • [1] A FIRST-IN-HUMAN (FIH) STUDY OF BCX4161, AN ORAL KALLIKREIN INHIBITOR, USING A TRANSLATIONAL PHARMACEUTICS PLATFORM
    Sweet, S.
    Collier, J.
    Connor, A.
    Paterson, M.
    Collis, P.
    Sheridan, W.
    El-Kattan, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S61 - S61
  • [2] Efficacy Correlates with Plasma Levels in Opus-1, a Proof-of-Concept Study of Oral Kallikrein Inhibitor BCX4161 As a Prophylaxis Against Attacks of Hereditary Angioedema (HAE)
    Aygoeren-Puersuen, Emel
    Magerl, Markus
    Graff, Jochen
    Martinez-Saguer, Inmaculada
    Kreuz, Wolfhart
    Longhurst, Hilary
    Nasr, Iman
    Bas, Murat
    Strassen, Ulrich
    Zong, Jian
    Fang, Lei
    Cornpropst, Melanie
    Dobo, Sylvia
    Collis, Phil
    Sheridan, William
    Maurer, Marcus
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB192 - AB192
  • [3] BCX4161, an Oral Kallikrein Inhibitor, Showed Significant Benefits on Reducing Disease Burden and Improving Quality of Life in Subjects with Hereditary Angioedema in the Opus-1 Study
    Magerl, Markus
    Aygoeren-Puersuen, Emel
    Graff, Jochen
    Martinez-Saguer, Inmaculada
    Kreuz, Wolfhart
    Longhurst, Hilary
    Nasr, Iman
    Bas, Murat
    Strassen, Ulrich
    Weller, Karsten
    Fang, Lei
    Cornpropst, Melanie
    Dobo, Sylvia
    Collis, Phil
    Sheridan, William
    Maurer, Marcus
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2015, 135 (02) : AB278 - AB278
  • [4] Long-acting potential of suprachoroidally delivered BCX4161, a selective plasma kallikrein inhibitor, for diabetic macular edema
    Muya, Leroy
    El-Kattan, Yahya
    Kansara, Viral
    Babu, Yarlagadda
    Ciulla, Thomas A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [5] PHARMACOKINETICS AND PHARMACODYNAMICS OF BCX7353, AN ORAL PLASMA KALLIKREIN INHIBITOR, IN HEALTHY JAPANESE SUBJECTS
    Cornpropst, M.
    Dobo, S.
    Collis, P.
    Collier, J.
    Sheridan, W.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S33 - S33
  • [6] Safety, pharmacokinetics, and pharmacodynamics of avoralstat, an oral plasma kallikrein inhibitor: phase 1 study
    Cornpropst, M.
    Collis, P.
    Collier, J.
    Babu, Y. S.
    Wilson, R.
    Zhang, J.
    Fang, L.
    Zong, J.
    Sheridan, W. P.
    ALLERGY, 2016, 71 (12) : 1676 - 1683
  • [7] SAFETY AND TOLERABILITY OF ONCE-DAILY ORAL KALLIKREIN INHIBITOR BCX7353 IN PHASE 3 APEX-2 HAE STUDY
    Riedl, M.
    Lumry, W.
    Banerji, A.
    Aygoren-Pursun, E.
    Bernstein, J.
    Maurer, M.
    Cicardi, M.
    Christiansen, S.
    Zuraw, B.
    Dobo, S.
    Cornpropst, M.
    Iocca, H.
    Nagy, E.
    Murray, S.
    Collis, P.
    Sheridan, W.
    Johnston, D.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S28 - S29
  • [8] Pharmacokinetic and Safety Study of Single and Multiple Oral Doses of Safinamide in Healthy Chinese Volunteers
    Jing, Sun
    Yuan, Yaozong
    Leuratti, Chiara
    Vaja, Valentina
    Cattaneo, Carlo
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (11): : 1104 - 1113
  • [9] A phase 1 pharmacokinetic study of oral NEPA, the fixed combination of netupitant and palonosetron, in Chinese healthy volunteers
    Rui Chen
    Hongyun Wang
    Wen Zhong
    Salvatore Chessari
    Corinna Lanzarotti
    Alberto Bernareggi
    Pei Hu
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 387 - 396
  • [10] A phase 1 pharmacokinetic study of oral NEPA, the fixed combination of netupitant and palonosetron, in Chinese healthy volunteers
    Chen, Rui
    Wang, Hongyun
    Zhong, Wen
    Chessari, Salvatore
    Lanzarotti, Corinna
    Bernareggi, Alberto
    Hu, Pei
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (03) : 387 - 396
12345